natgillin/translations-raw huggingface dataset:
Muscle spasm and cramps, musculoskeletal pain including myalgia9, arthralgia, bone pain10
Spazam mišića i grčevi, mišićno-koštana bol uključujući mialgiju9, artralgiju,
This time-to-event endpoint is strongly affected by the high crossover rate from IFN+Ara-C to imatinib.
Na to vrijeme-do događaja kao cilj ispitivanja je snažno utjecala visoka stopa prelazaka sa IFN+Ara-C na imatinib.
• Adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
(KML) s pozitivnim Philadelphia (Ph+) kromosomom (bcr-abl), u kojih se transplantacija koštane srži ne smatra prvom linijom liječenja.
Stop imatinib until ANC ≥ 1.5 x 109/l and platelets ≥ 75 x 109/l.
Ukinuti imatinib sve dok ABN ne bude ≥1,5 x 109/l i trombociti ≥75 x 109/l.
Dose increases from 400 mg to 600 mg or 800 mg in patients with chronic phase disease, or from 600 mg to a maximum of 800 mg (given as 400 mg twice daily) in patients with accelerated phase or blast crisis may be considered in the absence of severe adverse drug reaction and severe non-leukaemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response.
Povećanja doze sa 400 mg na 600 mg ili 800 mg u bolesnika s kroničnom fazom bolesti ili od 600 mg do maksimalno 800 mg (dano kao 400 mg dvaput na dan) u bolesnika s ubrzanom fazom ili s blastičnom krizom može se razmotriti u odsustvu teške nuspojave povezane s lijekom i teške neutropenije ili trombocitopenije nepovezane s leukemijom u sljedećim situacijama: progresija bolesti (u bilo kojem trenutku); neuspjeh u postizanju zadovoljavajućeg hematološkog odgovora nakon liječenja u trajanju od najmanje 3 mjeseca; neuspjeh u postizanju citogenetskog odgovora nakon 12 mjeseci liječenja; ili gubitak ranije postignutoga hematološkog i/ili citogenetskog odgovora.
- The other ingredients are calcium hydrogen phosphate, crospovidone and magnesium stearate.
- Ostali sastojci su kalcijev hidrogenfosfat, krospovidon i magnezijev stearat
The capsules are approximately 19 mm long and 7 mm wide.
Kapsule su približno 19 mm dugačke i 7 mm široke.
• Signs of infection such as fever, severe chills, sore throat or mouth ulcers.
• Znakovi infekcije kao što su vrućica, teška zimica, grlobolja ili čirevi u ustima.
• Muscle spasms with a fever, red-brown urine, pain or weakness in your muscles (signs of muscle problems).
• Grčevi mišića s vrućicom, crveno-smeđe obojena mokraća, bol ili slabost mišića (znakovi mišićnih problema).
HES/CEL (starting dose 100 mg)
HES/KEL (doza od 400 mg)
There is very limited experience in children with MDS/MPD, DFSP and HES/CEL.
Postoji vrlo ograničeno iskustvo kod djece s MDS/MPB-om, DFSP-om i
A limited number of patients were enrolled in phase I studies (n=10).
Limfatična blastična kriza U ispitivanjima faze I uključen je ograničeni broj bolesnika (n=10).
The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and ALL patients.
Supstancija selektivno inhibira proliferaciju te inducira apoptozu u Bcr-Abl pozitivnim staničnim linijama, kao i u svježim leukemijskim stanicama osoba s Ph+KML-om i ALL
9/l) and thrombocytopenias frequency of grade 3 or 4 neutropenias (ANC < 1.0 x 10 (platelet count < 50 x 109/l) being between 4 and 6 times higher in blast crisis and accelerated phase (59-64% and 44-63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia).
stupnja (ABN <1,0 x 109/l) i trombocitopenija (broj trombocita <50 x 109/l) bila između 4 i 6 puta veća u blastičnoj krizi i ubrzanoj fazi (59-64% i 44-63% za neutropeniju odnosno trombocitopeniju) u usporedbi s novodijagnosticiranim bolesnicima u kroničnoj fazi KML-a (16,7% neutropenija i 8,9%
The plasma protein binding of the N-demethylated metabolite is similar to that of the parent compound.
Vezanje N-demetiliranog metabolita za bjelančevine plazme je slično onom ishodne tvari.
An increased rate of opportunistic infections was observed with chronic imatinib treatment.
Kod kroničnog liječenja imatinibom zapažena je povećana stopa oportunističkih infekcija.
Seven years after the last patient had been recruited, the median duration of first-line treatment was 82 and 8 months in the imatinib and IFN arms, respectively.
Sedam godina nakon uključivanja posljednjeg bolesnika, medijan trajanja prve linije liječenja bio je 82 mjeseca u kraku koji je primao imatinib, odnosno 8 mjeseci u kraku koji je primao IFN.
Rates of complete haematological response, major cytogenetic response and complete cytogenetic response on first-line treatment were estimated using the Kaplan-Meier approach, for which nonresponses were censored at the date of last examination.
Stope potpunog hematološkog odgovora, velikog citogenetskog odgovora (MCyR) i potpunog citogenetskog odgovora (CCyR) za prvu liniju liječenja procijenjene su korištenjem KaplanMeierovog pristupa, pri čemu su izostanci odgovora izostavljeni kod datuma zadnjeg pregleda.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and inhibits PDGF- mediated cellular events.
Imatinib je također inhibitor receptorskih tirozin kinaza za faktor rasta koji potječe od trombocita (PDGF), PDGF-R, te inhibira stanična zbivanja posredovana PDGF-om.
Pruritus, face oedema, dry skin, erythema, alopecia, night sweats, photosensitivity reaction
Svrbež, edem lica, suhoća kože, eritem, alopecija, noćno znojenje,
A total of 26 paediatric patients of age < 18 years with either chronic phase CML (n=11) or CML in blast crisis or Ph+ acute leukaemias (n=15) were enrolled in a dose-escalation phase I trial.
<18 godina bilo s kroničnom fazom KML-a (n=11), bilo s KML-om u blastičnoj krizi ili Ph+ akutnim leukemijama (n=15).
If cytopenia persists for 2 weeks, reduce further to 300 mg.
Ako citopenija potraje 2 tjedna, dozu ponovno smanjiti na 300 mg.
Overall, in patients receiving first-line imatinib, the average daily dose delivered was 406 ±76 mg.
Ukupno gledajući, prosječna vrijednost dnevne doze dane bolesnicima koji su primali prvu liniju liječenja imatinibom iznosila je 406 ± 76 mg.
Imatinib Teva is indicated for
Teva je indiciran za
PLIVA Croatia Ltd. Prilaz baruna Filipovica 25
Prilaz baruna Filipovića 25
30 film-coated tablets 30x1 film-coated tablets 90 film-coated tablets 90x1 film-coated tablets
30 filmom obloženih tableta 30x1 filmom obloženih tableta 90 filmom obloženih tableta 90x1 filmom obloženih tableta
If you are unable to swallow the tablets, you can dissolve them in a glass of still water or apple juice:
Ako niste u stanju progutati tablete, možete ih otopiti u čaši negazirane vode ili soka od jabuke:
The capsules are approximately 23 mm long and 9 mm wide.
Kapsule su približno 23 mm dugačke i 9 mm široke.
Thyroid-stimulating hormone (TSH) levels should be closely monitored in such patients.
U takvih bolesnika trebaju se pažljivo pratiti razine tireotropina (TSH).
There was more myelosuppression seen in CML patients than in GIST, which is probably due to the underlying disease.
U bolesnika s KML-om uočen je veći postotak mijelosupresije, nego u bolesnika s GIST-om, što je vjerojatno uzrokovano osnovnom bolešću.
FIP1L1-PDGFRα fusion kinase was identified.
U 61 od tih 117 bolesnika identificirana je fuzijska kinaza FIP1L1-PDGFRα.
20x1 hard capsules 60 hard capsules 60x1 hard capsules 120 hard capsules 120x1 hard capsules 180x1 hard capsules
20x1 tvrdih kapsula 60 tvrdih kapsula 60x1 tvrdih kapsula 120 tvrdih kapsula 120x1 tvrdih kapsula 180x1 tvrdih kapsula
Imatinib Teva inhibits the growth of these cells.
Imatinib Teva inhibira rast ovih stanica.
Very common (may affect more than 1 in 10 people) or common (may affect up to 1 in 10 people):
Vrlo česte (mogu se javiti kod više od 1 na 10 ljudi) ili česte (mogu se javiti kod manje od 1 na 10 ljudi):
Isolated cases of imatinib overdose have been reported spontaneously and in the literature.
Zabilježeni su izolirani spontani i literaturni slučajevi predoziranja imatinibom.
31-546, Krakow Poland
Mogilska 80. 31-546, Krakow Poljska
There is no experience in children with CML below 2 years of age and with Ph+ALL below 1 year of age (see section 5.1).
Ne postoji iskustvo kod djece s KML-om mlađe od 2 godine i djece mlađe od 1 godine s Ph+ ALL
Major molecular response criteria: in the peripheral blood reduction of ≥ 3 logarithms in the amount of Bcr-Abl transcripts (measured by real-time quantitative reverse transcriptase PCR assay) over a standardised baseline.
Kriteriji velikog molekularnog odgovora: u perifernoj krvi, sniženje ≥3 logaritma u količini Bcr
Teva Pharma Belgium N.V./S.A./AG
Teva Pharma Belgium N.V./S.A./AG , Belgique/Belgien
The European Medicines Agency has waived the obligation to submit the results of studies with imatinib in all subsets of the paediatric population in Philadelphia chromosome (bcr-abl translocation)positive chronic myeloid leukaemia (see section 4.2 for information on paediatric use).
Europska Agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka imatiniba u svim podskupinama pedijatrijske populacije s Ph+KML-om (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Accelerated phase is defined by the presence of any of the following: blasts ≥ 15% but < 30% in blood or bone marrow, blasts plus promyelocytes ≥ 30% in blood or bone marrow (providing < 30% blasts), peripheral blood basophils ≥ 20%, platelets < 100 x 109/l unrelated to therapy.
Ubrzana faza se definira prisutnošću bilo kojeg od sljedećih kriterija: blasti ≥15% ali <30% u krvi ili koštanoj srži, blasti plus promijelociti ≥30% u krvi ili koštanoj srži (što daje <30% blasta), bazofili u perifernoj krvi ≥20%, trombociti <100 x 109/l nevezano uz terapiju.
doses)iii: days 2 and 3
6 doza)iii: Dani 2 i 3
• Rash, red skin with blisters on the lips, eyes, skin or mouth, peeling skin, fever, raised red or purple skin patches, itching, burning sensation, pustular eruption (signs of skin problems).
• Osip, crvenilo kože s mjehurićima na usnama, očima, koži ili u ustima, ljuštenje kože, vrućica, izdignuti crveni ili ljubičasti plikovi na koži, svrbež, osjećaj žarenja, pojava gnojnih mjehurića
4 Flushing was most common in GIST patients and bleeding (haematoma, haemorrhage) was most common in patients with GIST and with transformed CML (CML-AP and CML-BC).
4 Crvenilo uz osjećaj vrućine je bilo najčešće u bolesnika s GIST-om, a krvarenje (hematomi, hemoragija) je bilo najčešće u bolesnika s GIST-om i s transformiranim KML-om (ubrzana faza i blastična kriza).
How to take Imatinib Teva
Kako uzimati Imatinib Teva
Dose increases from 340 mg/m2 daily to 570 mg/m2 daily (not to exceed the total dose of 800 mg) may be considered in children in the absence of severe adverse drug reaction and severe non-leukaemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response.
U djece se može razmotriti povećanje doze od 340 mg/m2 na dan do 570 mg/m2 na dan (ne smije se prekoračiti ukupna doza od 800 mg) u odsustvu teških nuspojava povezanih s lijekom i teške neutropenije ili trombocitopenije nepovezane s leukemijom u slijedećim situacijama: progresija bolesti (u bilo kojem trenutku); neuspjeh u postizanju zadovoljavajućeg hematološkog odgovora nakon liječenja u trajanju od najmanje 3 mjeseca; neuspjeh u postizanju citogenetskog odgovora nakon 12 mjeseci liječenja; ili gubitak ranije postignutoga hematološkog i/ili citogenetskog odgovora.
The printing ink is composed of shellac, iron oxide black (E172) and propylene glycol.
Tinta za označavanje se sastoji od šelaka, crnog željezovog oksida (E172) i propilenglikola.
This inhibition has not been observed in vivo after the administration of imatinib 400 mg and paracetamol 1000 mg. Higher doses of imatinib and paracetamol have not been studied.
Ovakva inhibicija nije uočena in vivo nakon primjene imatiniba u dozi od 400 mg i paracetamola u dozi od
Therefore, caution is recommended when administering imatinib with CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel and quinidine).
Zbog toga se preporučuje oprezno postupati kada se imatinib primjenjuje sa supstratima CYP3A4 s uskom terapijskom širinom (npr. ciklosporin, pimozid, takrolimus, sirolimus, ergotamin, diergotamin, fentanil, alfentanil, terfenadin, bortezomib,
20x1 film-coated tablets 60 film-coated tablets 60x1 film-coated tablets 120 film-coated tablets 120x1 film-coated tablets 180x1 film-coated tablets
20x1 filmom obloženih tableta 60 filmom obloženih tableta 60x1 filmom obloženih tableta 120 filmom obloženih tableta 120x1 filmom obloženih tableta 180x1 filmom obloženih tableta
Caution should be used when taking imatinib with protease inhibitors, azole antifungals, certain macrolides, CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel, quinidine) or warfarin and other coumarin derivatives (see section 4.5).
Potreban je oprez kada se imatinib uzima s inhibitorima proteaze, azolnim antimikoticima, određenim makrolidima, CYP3A4 supstratima s uskim terapijskim prozorom (npr. ciklosporin, pimozid, takrolimus, sirolimus, ergotamin, diergotamin, fentanil, alfentanil, terfenadin, bortezomib, docetaksel, kvinidin) ili varfarinom i drugim derivatima kumarina (vidjeti dio 4.5).
5 Pleural effusion was reported more commonly in patients with GIST and in patients with transformed CML (CML-AP and CML-BC) than in patients with chronic CML.
5 Pleuralni izljev je češće zabilježen u bolesnika s GIST-om i u bolesnika s transformiranim KML-om (KML-ubrzana faza i KML-blastična kriza), nego u bolesnika s kroničnim KML-om.
Acute respiratory failure11*, interstitial lung disease* Gastrointestinal disorders Very common
Akutno zatajenje disanja11*, intersticijska plućna bolest* Poremećaji probavnog sustava Vrlo često
If any of these apply to you, tell your doctor before taking Imatinib Teva
Ako se bilo što od navedenog odnosi na Vas, obavijestite svog liječnika prije uzimanja Imatinib
Pack sizes of 60 or 120 film-coated tablets in blisters.
Veličine pakiranja od 60 ili 120 filmom obloženih tableta u blisterima.
The tablets are approximately 20 mm long and 10 mm wide.
Tablete su približno 20 mm dugačke i 10 mm široke.
Complete CyR n (%) Partial CyR n (%)
Potpuni CyR n (%)
Patients were treated at doses of imatinib of 260 mg/m2/day (n=5), 340 mg/m2/day (n=9), 440 mg/m2/day (n=7) and 570 mg/m2/day (n=5).
340 mg/m2/dan (n=9), 440 mg/m2/dan (n=7), te 570 mg/m2/dan (n=5).
The most commonly reported (≥ 10%) drug-related adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash.
Najčešće zabilježene nuspojave (≥10%), u obje bolesti koje su povezane s primjenom lijeka, bile su blaga mučnina, povraćanje, proljev, bol u trbuhu, umor, bol u mišićima, grčevi u mišićima i osip.
One phase II, open label, multicentre clinical trial (study B2225) was conducted including 12 patients with DFSP treated with imatinib 800 mg daily.
Provedeno je jedno otvoreno, multicentrično kliničko ispitivanje faze II (studija B2225) koje je uključivalo 12 bolesnika s DFSP-om liječenih imatinibom u dozi od 800 mg na dan.
Whereas an estimated 96% (93%) of patients with CCyR (PCyR) at 12 months were free of progression to accelerated phase/blast crisis at 84 months, only 81% of patients without MCyR at 12 months were free of progression to advanced CML at 84 months (p<0.001 overall, p=0.25 between CCyR and PCyR).
81% bolesnika bez MCyR nakon 12 mjeseci bilo bez progresije u uznapredovali KML nakon 84 mjeseca (p<0,001 ukupno, p=0,25 između CCyR-a i PCyR-a).
Target organs for neoplastic changes were the kidneys, urinary bladder, urethra, preputial and clitoral gland, small intestine, parathyroid glands, adrenal glands and non-glandular stomach.
Ciljni organi neoplastičkih promjena bili su bubrezi, mokraćni mjehur, uretra, žlijezda prepucija i klitorisa, tanko crijevo, paratireoidne žlijezde, nadbubrežne žlijezde i ne-žljezdani dio želuca.
Resume treatment with imatinib at 600 mg.
Nastaviti imatinib u dozi od 600 mg.
6-MP (75 mg/m2/day, PO): days 8-28
6-MP (75 mg/m2/dan, p.o.): dani 8-28
10 Musculoskeletal pain and related events were more commonly observed in patients with CML than in GIST patients.
10 Mišićno-koštana bol i vezane nuspojave su češće uočeni u bolesnika s KML-om, nego u bolesnika s GIST-om.
• Pale skin, feeling tired and breathlessness and having dark urine (signs of low levels of red blood cells).
• Blijeda koža, umor i gubitak daha te tamno obojena mokraća (znakovi snižene razine crvenih krvnih stanica).
Liver function (transaminases, bilirubin, alkaline phosphatase) should be monitored regularly in patients receiving imatinib.
U bolesnika koji primaju imatinib potrebno je redovito kontrolirati parametre jetrene funkcije (transaminaze, bilirubin, alkalna fosfataza).
MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U
Iron oxide black (E172) Propylene glycol
crnog željezovog oksida (E172) i propilenglikola.
9/l.
9/l i trombociti
• Feeling dizzy or weak.
• Omaglica ili slabost.
Treatment schedule: On the basis of the existing data, imatinib has been shown to be effective and safe when administered at 600 mg/day in combination with chemotherapy in the induction phase, the consolidation and maintenance phases of chemotherapy (see section 5.1) for adult patients with newly diagnosed Ph+ ALL.
600 mg/ dan u kombinaciji s kemoterapijom u indukcijskoj, konsolidacijskoj te fazi održavanja kemoterapije (vidjeti dio 5.1) u odraslih bolesnika s novodijagnosticiranom Ph+ ALL.
600 mg to be taken as 1 tablet of 400 mg plus 2 tablets of 100 mg or as 1 ½ tablets of 400 mg once a day.
600 mg se uzima kao 1 tableta od 400 mg plus 2 tablete od 100 mg ili kao 1 ½ tableta od 400 mg jednom na dan.
If a severe non-haematological adverse reaction develops with imatinib use, treatment must be withheld until the event has resolved.
Ako se tijekom primjene imatinibom razvije teška nehematološka nuspojava, liječenje se mora prekinuti sve do oporavka od nuspojava.
Because of known increased risks of bleeding in conjunction with the use of imatinib (e.g. haemorrhage), patients who require anticoagulation should receive low-molecular-weight or standard heparin, instead of coumarin derivatives such as warfarin.
bolesnici kojima je potrebna antikoagulacija trebaju primati heparin niske molekularne težine ili standardni heparin, umjesto kumarinskih derivata kao što je varfarin.
The doctor will tell you how many capsules of Imatinib Teva to give to your child.
Liječnik će Vam reći koliko kapsula Imatiniba Teva trebate dati djetetu.
In this study, 14 patients with HES/CEL were treated with 100 mg to 1,000 mg of imatinib daily.
U tom kliničkom ispitivanju, 14 bolesnika s HES/KELom je liječeno imatinibom u dozi od 100 mg do 1000 mg na dan.
- If you are being treated for CML:
Ako se liječite zbog KML-a:
Imatinib was teratogenic in rats when administered during organogenesis at doses ≥ 100 mg/kg, approximately equal to the maximum clinical dose of 800 mg/day, based on body surface area.
Imatinib je bio teratogen u štakora kada je primjenjivan tijekom organogeneze u dozama ≥100 mg/kg,
The doctor will tell you how many tablets of Imatinib Teva to give to your child.
Liječnik će Vam reći koliko tableta Imatiniba Teva trebate dati djetetu.
Posology for MDS/MPD The recommended dose of Imatinib Teva is 400 mg/day for adult patients with MDS/MPD.
Doziranje za MDS/MPD Za odrasle bolesnike s MDS/MPD-om preporučena doza Imatiniba Teva iznosi 400 mg/dan.
One open-label, multicentre, phase II clinical trial (study B2225) was conducted testing imatinib in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases.
Provedeno je jedno otvoreno, multicentrično kliničko ispitivanje faze II (studija B2225) za ispitivanje imatiniba u raznim populacijama bolesnika koji pate od životno ugrožavajućih bolesti povezanih s Abl, Kit ili PDGFR protein tirozin kinazama.
DEX (6 mg/m2/day PO): days 1-5; 29-33 6-MP (75 mg/m2/day, PO): days 8-28
DEX (6 mg/m2/dan, p.o.): dani 1-5; 29-33 6-MP (75 mg/m2/dan, p.o.): dani 8-28
• Nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint discomfort associated with abnormal laboratory test results (e.g. high potassium, uric acid and calcium levels and low phosphorous levels in the blood).
• Mučnina, nedostatak zraka, nepravilni otkucaji srca, zamućenje mokraće, umor i/ili osjećaj nelagode u zglobovima udruženi s poremećenim nalazima laboratorijskih pretraga (npr. visoke razine kalija, mokraćne kiseline i kalcija te niske fosfora kalcija u krvi).
(Best response rates)
(znakovi kožnih problema).
Palmoplantar erythrodysesthesia syndrome*, lichenoid keratosis*, lichen planus*, toxic epidermal necrolysis*, drug rash with eosinophilia and systemic symptoms (DRESS)*, pseudoporphyria* Musculoskeletal and connective tissue disorders Very common
Sindrom palmoplantarne eritrodisestezije*, lihenoidna keratoza*, lichen planus*, toksična epidermalna nekroliza*, osip uzrokovan lijekom s eozinofilijom i sistemskim simptomima (DRESS)* , pseudoporfirija*
Reproductive system and breast disorders Uncommon
Poremećaji reproduktivnog sustava i dojki Manje često
In newly diagnosed chronic phase CML grade 4 neutropenia (ANC < 0.5 x 109/l) and thrombocytopenia (platelet count < 10 x 109/l) were observed in 3.6% and < 1% of patients, respectively.
<0,5 x 109/l) i trombocitopenija (broj trombocita <10 x 109/l) zapažene su u 3,6% odnosno <1%
• Swelling such as round your ankles or puffy eyes.
• Oticanje kao što je oticanje gležnjeva ili otečene oči.
The safety and efficacy of imatinib in children with MDS/MPD, DFSP and HES/CEL aged less than 18 years of age have not been established in clinical trials.
Sigurnost i djelotvornost imatiniba u djece s MDS/MPB-om, DFSP-om i HES/KEL-om mlađe od
VCR 1.3 g/m2 i.v., day 1; Prednisolone 60 mg/m2 oral, days 1-5
VCR 1,3 g/m2 i.v., dan 1; Prednizolon 60 mg/m2 peroralno, dani 1-5
Calcium hydrogen phosphate Crospovidone
Jezgra tablete kalcijev hidrogenfosfat krospovidon magnezijev stearat
- The other ingredients are mannitol, crospovidone, magnesium stearate and silica colloidal anhydrous.
- Drugi sastojci su manitol, krospovidon, magnezijev stearat i bezvodni koloidni silicijev dioksid.
Patients should be tested for
Potrebno je imati na umu da bolesnici s
If you take more Imatinib Teva than you should If you have accidentally taken too many tablets, talk to your doctor straight away.
Ako ste zabunom uzeli previše tableta, odmah se obratite liječniku.
Table 4 Chemotherapy regimen used in combination with imatinib
Tablica 4 Režim kemoterapije korišten u kombinaciji s imatinibom Studija ADE10
FIP1L1-PDGFRα-positive in other 3 published reports.
Dodatna četiri bolesnika s HES-om bila su pozitivna za FIP1L1-PDGFRα u ostala 3 objavljena slučaja.
DEX 10 mg/m2 oral, days 6-7, 13-16; VCR 1 mg i.v., days 7, 14;
Indukcija remisije DEX 10 mg/m2 peroralno, dani 6-7, 13-16; VCR 1 mg i.v., dani 7, 14;
Hypokalaemia, increased appetite, hypophosphataemia, decreased appetite, dehydration, gout, hyperuricaemia, hypercalcaemia,
Hipokalijemija, povećan apetit, hipofosfatemija, smanjen apetit, dehidracija,